Vera Therapeutics (NASDAQ:VERA) Trading Up 7.7% – What’s Next?

Vera Therapeutics, Inc. (NASDAQ:VERA)’s stock price shot up 7.7% during trading on Monday . The stock traded as high as $37.91 and last traded at $37.7750. Approximately 248,933 shares changed hands during trading, a decline of 78% from the average session volume of 1,132,225 shares. The stock had previously closed at $35.09.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Evercore set a $91.00 price objective on shares of Vera Therapeutics in a report on Friday, May 15th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $90.00 price target on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Wolfe Research upgraded Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price objective for the company in a research note on Wednesday, March 11th. TD Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $60.00 target price on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $78.00.

Vera Therapeutics Price Performance

The company has a market capitalization of $2.74 billion, a price-to-earnings ratio of -6.90 and a beta of 0.93. The stock has a fifty day simple moving average of $36.24 and a 200-day simple moving average of $41.53. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.64 and a quick ratio of 13.64.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period last year, the firm posted ($0.81) earnings per share. On average, equities research analysts anticipate that Vera Therapeutics, Inc. will post -6.23 EPS for the current year.

Insider Transactions at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 18,500 shares of the stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $36.74, for a total transaction of $679,690.00. Following the sale, the chief executive officer directly owned 216,744 shares of the company’s stock, valued at approximately $7,963,174.56. This represents a 7.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 15.90% of the company’s stock.

Institutional Investors Weigh In On Vera Therapeutics

Several hedge funds have recently modified their holdings of VERA. Price T Rowe Associates Inc. MD raised its holdings in Vera Therapeutics by 49.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company’s stock worth $276,595,000 after purchasing an additional 1,795,537 shares during the period. Deerfield Management Company L.P. grew its holdings in Vera Therapeutics by 8.8% in the third quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock valued at $105,812,000 after purchasing an additional 293,040 shares during the period. Vanguard Group Inc. grew its holdings in Vera Therapeutics by 11.9% in the fourth quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock valued at $180,805,000 after purchasing an additional 379,748 shares during the period. Vestal Point Capital LP increased its position in shares of Vera Therapeutics by 24.0% in the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock valued at $73,036,000 after buying an additional 600,000 shares in the last quarter. Finally, Eversept Partners LP raised its stake in shares of Vera Therapeutics by 9.4% during the 4th quarter. Eversept Partners LP now owns 3,072,304 shares of the company’s stock worth $155,581,000 after buying an additional 264,468 shares during the period. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.